About Dr. Russell Dahl /

Dr. Dahl is a former Professor of Neuroscience and Medicinal Chemistry and received his Ph.D. in organic chemistry from the University of California, San Diego as a DuPont pharmaceuticals fellow and has additional training in molecular pharmacology from Stanford University.

Learn More About Dr. Dahl's Work at Neurodon

Read about the latest achievements at Neurodon, which uses Calcium ATPase research to develop treatments for Alzheimer’s, Parkinson’s, and more.

Dr. Dahl has co-authored over 80 scientific publications and is an inventor on over 50 patent applications. For more than a decade, his focus has been on intracellular calcium regulation and Calcium ATPase.  He is one of the top experts in the country.

Currently, Dr. Dahl is the CEO and scientific founder of Neurodon, a privately held biotech company that specializes in developing drugs that target cellular health. 

Dr. Russell Dahl

He has identified a small molecule Calcium ATPase (SERCA) stimulator which has been shown in animal studies that improves memory and cognition in Alzheimer’s, reduces dyskinesia in Parkinson’s, control blood sugar in diabetes, and improves cardiac function in heart failure.

DR.Russel Dahl's Research

After coming across Dr. Dahl’s journal articles during her research, Brunde contacted Dr. Dahl and they quickly developed a meaningful relationship centered around their mutual knowledge and passion for Calcium ATPase.  They have since jointed efforts to promote the education of both the public at large and the medical community regarding Calcium ATPase, in addition to the development of drugs to target this enzyme. 


Dr. Dahl serves as a medical advisor and editor for the book and Brunde serves on the board of directors at Neurodon.  Both hope to reduce suffering and save many lives through their efforts.

Recent articles related to Calcium ATPase:

  1. A new target for Alzheimer’s disease: A small molecule SERCA activator is neuroprotective in vitro and improves memory and cognition in APP/PS1 mice.
    Krajnak K, Dahl R.  Bioorg Med Chem Lett. 2018 May 15;28(9):1591-1594.

  2. A new target for Parkinson’s disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats.
    Dahl R.Bioorg Med Chem. 2017 Jan 1;25(1):53-57.

  3. Small Molecular Allosteric Activator of the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) Attenuates Diabetes and Metabolic Disorders.
    Kang S, Dahl R, Hsieh W, Shin A, Zsebo KM, Buettner C, Hajjar RJ, Lebeche D.
    J Biol Chem. 2016 Mar 4;291(10):5185-98.

  4. Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure.
    Kho C, Lee A, Jeong D, Oh JG, Gorski PA, Fish K, Sanchez R, DeVita RJ, Christensen G, Dahl R, Hajjar RJ. Nat Commun. 2015 Jun 12;6:7229.

If you are committed to making changes, you will see results, and your body will thank you. 

The journey to reclaim your health can be frightening and stressful. However, you’re not alone. Join subscribers like you to get the most up-to-date information on Calcium ATPase.

Get my newsletter and preview a chapter of my book for free.